^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TSLPR-directed CAR T
i
Other names: TSLPR-directed CAR T, TSLPR CAR-T
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fred Hutchinson Cancer Center
Drug class:
TSLPR-targeted CAR-T immunotherapy
Related drugs:
3years
Immunotherapeutic Targeting of TSLPR with Chimeric Antigen Receptor T Cells in AML (ASH 2021)
We further demonstrate that CAR T cells targeting TSLPR were effective in eliminating AML cells in vitro and in vivo . Given that TSLPR is highly expressed in the KMT2A-rearranged AML, a subtype that is associated with poor outcomes, TSLPR-directed CAR T cells represent a promising immunotherapy for this high-risk AML subset.
CAR T-Cell Therapy • IO biomarker
|
KMT2A (Lysine Methyltransferase 2A) • CRLF2 (Cytokine Receptor Like Factor 2)
|
MLL rearrangement • KMT2A expression • MLL fusion
|
TSLPR-directed CAR T
Share via
